$PODD News

Insulet (PODD) Could Be 11% Undervalued On Omnipod Discover Launch

Insulet (NASDAQ:PODD): A Growth-at-a-Reasonable-Price Case With Strong Expansion

Jefferies Maintains Buy on Insulet, Lowers Price Target to $190

Insulet Announces Omnipod Discover Now Available in U.S.

Insulet Reports Q2 2026 Results: Full Earnings Call Transcript

Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150

Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026

Insulet (NASDAQ:PODD) Offers Affordable Growth With Strong Fundamentals

Insulet (PODD) Stock May Trade At A Discount To Fair Value

Insulet (PODD) Reworked Its Debt, Is The Stock Still Cheap?

Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum

Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?

Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum

BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status

Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Artisan Sold Insulet (PODD) Due to Competition Concerns

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds

Insulet Corporation: Strong Growth Meets A New Execution Problem